Who said this wasn't a class effect?
"New York-based Pfizer said yesterday that a trial carried out by the
National Cancer Institute into the use of Celebrex to treat cancerous
tumours, was halted after results showed "an approximately 2.5-fold
increase" in the risk of non-fatal heart attacks in patients."
http://www.guardian.co.uk/business/story/0,,1376455,00.html
--
Simon Child
www.GPUK.net
www.woodbanksurgery.nhs.uk
|